Profiling the Skin Microbiome in Response to Altreno in Acne Patients

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study objective is to characterize the shift in the diversity and abundance of the skin microbial community at baseline and in response to Altreno monotherapy as compared to benzoyl peroxide (BPO) 2.5% leave-on gel monotherapy in acne patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: Ortho Dermatologics
• Treatments: Benzoyl Peroxide

Criteria

Inclusion Criteria:

• A confirmed diagnosis of acne that warrants initiating topical medications.

• Denies use of any prescribed systemic acne treatments in the past 30 days.

• Denies use of any prescribed topical medications in the past 30 days.

• Denies use of any OTC topical acne medications in the past 14 days.

• Denies use of any emollients in the past 24 hours (if feasible).

• Denies bathing or facial washing in the past 12 hours (if feasible).

• Willingness to adhere to the recommended topical regimen during the duration of the study.

Exclusion Criteria:

• Women who are pregnant, breastfeeding, or planning to get pregnant during the study.

• Use of any investigational drug(s) in the past 3 months.